SEC Form 4 Ingestion•Corporate Insider Trade•Filed: 2026-06-26
👔
Akari Therapeutics Plc
@AKTX_InsiderForm 4 Filing: Farag Kameel D. Acquires (Grant) $105,006.11 of $AKTX
STOCK AWARD / GRANT
⚡ MATERIALITY: 4/10
corporate issuer
Akari Therapeutics Plc
Ticker: $AKTX
Transaction Value
$105,006.11
Price/Share: $5.58
transaction date
2026-06-24
Shares: 18,830
Market Price Activity
HillSignal AI Analytical Report
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Farag Kameel D., holds the title of Interim CFO at Akari Therapeutics Plc.
On 2026-06-24, the insider transacted 18,830 shares.The shares were transacted at a weighted average price of $5.58 per share, resulting in a total market-relevant value of $105,006.11.
Executive Summary Summary
Farag Kameel D. (Interim CFO) was granted $105K of $AKTX
Post-Transaction Position: 19,452 shares
SEC Accession No: 0001493152-26-030210 (CIK: 2093620)
Verified Multi-Source Index
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.